Phase
Condition
Pain (Pediatric)
Treatment
N/AClinical Study ID
Ages 18-120 All Genders
Study Summary
Eligibility Criteria
Inclusion
DISEASE CHARACTERISTICS:
Diagnosis of cancer
Concurrently receiving or has previously received chemotherapy and is scheduled for at least 3 additional courses of chemotherapy
Each course of chemotherapy must be at least 2 weeks in duration
No concurrent radiotherapy or interferon therapy
Brief Fatigue Inventory question #3 "fatigue worst" score of 2 or greater 1 week after first chemotherapy course
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Not specified
Life expectancy
- At least 6 months
Hematopoietic
- Not specified
Hepatic
- No uncontrolled anemia
Renal
- Not specified
Cardiovascular
No history of clinically significant cardiac disease, including any of the following:
Unstable angina
Left ventricular hypertrophy
Ischemic echocardiogram changes
Chest pain
Arrhythmia
Other clinically significant manifestations of mitral valve prolapse in association with use of central nervous system stimulants (e.g., caffeine, amphetamines, or methylphenidate)
No uncontrolled hypertension
Gastrointestinal
Able to swallow medication
No narrowing (pathological or iatrogenic) or obstruction of the gastrointestinal tract
Other
No severe headaches
No glaucoma
No seizure disorder
No narcolepsy
No psychotic disorder
No Tourette's syndrome
No alcohol or drug abuse
Not pregnant or nursing
Fertile patients must use effective barrier contraception during and for at least 1 full menstrual cycle after study completion
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- No concurrent chronic corticosteroids
Radiotherapy
- See Disease Characteristics
Surgery
- Not specified
Other
No prior modafinil
At least 30 days since prior regular use of psychostimulants (e.g., amphetamines, methylphenidate, or pemoline) or monoamine oxidase inhibitors (MAOIs)
No concurrent alcohol
Concurrent acetaminophen with codeine or hydrocodone bitartrate allowed
Concurrent phenytoin allowed
Concurrent warfarin for anticoagulation and low-dose warfarin (1 mg by mouth daily) for maintenance of venous access devices allowed
Study Design
Study Description
Connect with a study center
MBCCOP - Gulf Coast
Mobile, Alabama 36606
United StatesSite Not Available
CCOP - Western Regional, Arizona
Phoenix, Arizona 85006-2726
United StatesSite Not Available
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California 95403
United StatesSite Not Available
Medical Center of Aurora - South Campus
Aurora, Colorado 80012-0000
United StatesSite Not Available
Boulder Community Hospital
Boulder, Colorado 80301-9019
United StatesSite Not Available
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado 80933
United StatesSite Not Available
CCOP - Colorado Cancer Research Program
Denver, Colorado 80224
United StatesSite Not Available
Porter Adventist Hospital
Denver, Colorado 80210
United StatesSite Not Available
Presbyterian - St. Luke's Medical Center
Denver, Colorado 80218
United StatesSite Not Available
Rocky Mountain Cancer Centers - Denver Rose
Denver, Colorado 80220
United StatesSite Not Available
St. Joseph Hospital
Denver, Colorado 80218-1191
United StatesSite Not Available
Swedish Medical Center
Englewood, Colorado 80112
United StatesSite Not Available
Sky Ridge Medical Center
Lone Tree, Colorado 80124
United StatesSite Not Available
Rocky Mountain Cancer Centers - Longmont
Longmont, Colorado 80501
United StatesSite Not Available
St. Mary-Corwin Regional Medical Center
Pueblo, Colorado 81004
United StatesSite Not Available
Rocky Mountain Cancer Centers - Thornton
Thornton, Colorado 80229
United StatesSite Not Available
MBCCOP - Hawaii
Honolulu, Hawaii 96813
United StatesSite Not Available
MBCCOP - University of Illinois at Chicago
Chicago, Illinois 60612-7323
United StatesSite Not Available
CCOP - Central Illinois
Decatur, Illinois 62526
United StatesSite Not Available
CCOP - Evanston
Evanston, Illinois 60201
United StatesSite Not Available
CCOP - Wichita
Wichita, Kansas 67214-3882
United StatesSite Not Available
CCOP - Kalamazoo
Kalamazoo, Michigan 49007-3731
United StatesSite Not Available
CCOP - Metro-Minnesota
St. Louis Park, Minnesota 55416
United StatesSite Not Available
CCOP - Kansas City
Kansas City, Missouri 64131
United StatesSite Not Available
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada 89106
United StatesSite Not Available
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York 13057
United StatesSite Not Available
CCOP - North Shore University Hospital
Manhasset, New York 11030
United StatesSite Not Available
CCOP - Southeast Cancer Control Consortium
Goldsboro, North Carolina 27534-9479
United StatesSite Not Available
CCOP - Columbus
Columbus, Ohio 43215
United StatesSite Not Available
CCOP - Dayton
Dayton, Ohio 45429
United StatesSite Not Available
CCOP - Columbia River Oncology Program
Portland, Oregon 97225
United StatesSite Not Available
CCOP - Greenville
Greenville, South Carolina 29615
United StatesSite Not Available
CCOP - Virginia Mason Research Center
Seattle, Washington 98101
United StatesSite Not Available
CCOP - Northwest
Tacoma, Washington 98405-0986
United StatesSite Not Available
CCOP - Marshfield Clinic Research Foundation
Marshfield, Wisconsin 54449
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.